Koers Cytori Therapeutics Inc Nasdaq
Aandelen
US23283K4022
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 3,4 mln. 3,18 mln. | Omzet 2025 * | 4,28 mln. 4 mln. | Marktkapitalisatie | 7,23 mln. 6,76 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -19 mln. -17,77 mln. | Nettowinst (verlies) 2025 * | -22 mln. -20,58 mln. | EV/omzet 2024 * | 2,13 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 1,69 x |
K/w-verhouding 2024 * |
-0,74
x | K/w-verhouding 2025 * |
-0,9
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 96,77% |
Recentste transcriptie over Cytori Therapeutics Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Marc Hedrick
CEO | Chief Executive Officer | 61 | 01-10-02 |
Andrew Sims
DFI | Director of Finance/CFO | 51 | 06-02-20 |
Pius Maliakal
CTO | Chief Tech/Sci/R&D Officer | - | 27-07-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Marc Hedrick
CEO | Chief Executive Officer | 61 | 01-10-02 |
Richard Hawkins
CHM | Chairman | 75 | 01-12-07 |
Robert Lenk
BRD | Director/Board Member | 75 | 01-03-20 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+1,51% | 42,75 mld. | |
+49,22% | 41,61 mld. | |
+8,57% | 41,34 mld. | |
-12,36% | 26,59 mld. | |
+8,92% | 25,49 mld. | |
-25,13% | 18,12 mld. | |
+29,17% | 12,24 mld. | |
-3,12% | 11,76 mld. | |
+6,35% | 11 mld. |